Deerfield Management Boosts Its Stake in OvaScience Inc (OVAS)

Deerfield Management, led by James E. Flynn, revealed in a filing with the Securities and Exchange Commission that it has upped its stake in OvaScience Inc (NASDAQ:OVAS) to 1.8 million shares from 605,600 shares held at the end of the fourth quarter of 2013. The current passive stake amasses 7.6% of the company’s common stock.

OvaScience Inc (NASDAQ:OVAS)

OvaScience Inc (NASDAQ:OVAS) is a global life sciences company that discovers, develops and commercializes new fertility treatments.

Recently, OvaScience Inc (NASDAQ:OVAS) conducted a public offering of 5.0 million shares of common stock at a price of $10.00 per share. The company will use the net proceed from the offering to fund OvaPrimeSM preclinical studies and the anticipated 2015 international launch, expand the AUGMENTSM international launch, establish an international subsidiary and for other general corporate purposes.

The underwriters of the public offering were granted a 30-day option to purchase up to an additional 750,000 shares of common stock of the company.

Last month, OvaScience posted its results for the fourth quarter and the fiscal year 2013. The net loss was 11.0 million, versus a net loss of $4.2 million in the fourth quarter of 2012. For the full year, the net loss amounted to $29.0 million, compared to $13.5 million in the previous year. The increase of the loss was due to a one-time charge of $4.7 million for a technology access fee, with respect to the company’s collaboration with Intrexon, and also due to the high personnel costs, which includes stock-based compensation.

In addition, during the last year, OvaScience Inc (NASDAQ:OVAS) issued $2.5 million of common stock to Intrexon under the collaboration agreement and the remainder will be paid in December 2014. There was also a rise in the research and development expense to $15.8 million in 2013, from $6.3 million in 2012.

Hal Mintz’s Sabby Capital is another hedge fund that is bullish on OvaScience Inc, which holds 152,336 shares, worth $1.4 million.

Last week, Christoph Westphal and Richard Aldrich, director at OvaScience Inc, purchased 100,000 shares. Michelle Dipp, President & CEO and Longwood Fund, L.p., a large shareholder of the company also purchased 100,000 shares each of OvaScience. All three insiders purchased the securities at the public offering price of $10.00 per share.

Deerfield Management focuses on healthcare companies and specializes in funding R&D, corporate transitions, managing hostile takeovers and financial advisory services.

Last month, Deerfield Management boosted its position in Auspex Pharmaceuticals Inc (NASDAQ:ASPX), by buying 700,000 shares and revealed owning 1.9 million shares of the company. The fund also added 350,000 shares of Cara Therapeutics Inc. (NASDAQ:CARA). The fund also added KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) to its equity portfolio, the previous month, and revealed holding 3.18 million shares of the company.

Disclosure: none

Recommended Readings:

Deerfield Management Further Raises Its Position in Auspex Pharmaceuticals Inc (ASPX)

Deerfield Management Adds Cara Therapeutics Inc. (CARA) To Its Equity Portfolio

Deerfield Management Reports New Stake in KaloBios Pharmaceuticals Inc (KBIO)

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!